Diffusion Kurtosis Imaging as a Prognostic Marker in Osteosarcoma Patients with Preoperative Chemotherapy

Table 4

Association of DKI with the OS and PFS of patients with osteosarcoma stratified by histological response.

Variable	OS			PFS
	Overall death/total	Log-rank	aHR (95% CI)	Pro/total	Log-rank	aHR (95% CI)
PRs ()
Pre MK		0.78			0.92
≥0.94	4/8		1.0	6/8		1.0
<0.94	5/9		0.8 (0.2-3.3)	6/9		0.9 (0.3-2.9)
Pre MD		0.24			0.12
≥1.32	7/15		1.0	10/15		1.0
<1.32	2/2		2.5 (0.5-12.3)	2/2		3.4 (0.6-18.9)
Post MK		0.12			0.47
≥0.80	5/8		1.0	6/8		1.0
<0.80	4/9		0.3 (0.1-1.4)	6/9		0.6 (0.2-2.0)
Post MD		0.08			0.07
≥1.66	2/6		1.0	3/6		1.0
<1.66	7/11		3.7 (0.7-18.7)	9/11		3.1 (0.8-11.7)
CR MK (%)		0.37			0.94
≥-16.89	5/9		1.0	6/9		1.0
<-16.89	4/8		0.5 (0.1-2.1)	6/8		0.9 (0.3-3.0)
CR MD (%)		0.04			0.26
≥13.53	1/5		1.0	3/5		1.0
<13.53	8/12		6.8 (0.8-58.0)	9/12		2.1 (0.5-7.8)
GRs ()
Pre MK		0.67			0.43
≥0.94	0/2		NA	0/2		NA
<0.94	1/11			3/11
Pre MD		0.58			0.73
≥1.32	1/10		NA	2/10		1.0
<1.32	0/3			1/3		1.5 (0.1-16.4)
Post MK		0.73			0.11
≥0.80	0/1		NA	1/1		1.0
<0.80	1/12			2/12		0.2 (0.1-2.0)
Post MD		0.73			0.60
≥1.66	1/12		NA	3/12		NA
<1.66	0/1			0/1
CR MK (%)		0.67			0.44
≥-16.89	0/2		NA	1/2		1.0
<-16.89	1/11			2/11		0.4 (0.1-4.4)
CR MD (%)		0.73			0.60
≥13.53	1/12		NA	3/12		NA
<13.53	0/1			0/1

aHR: adjusted for age, sex, location, stage, pathological subtype, and treatment. MD is given in .